Page last updated: 2024-08-17

tributyrin and Prostatic Neoplasms

tributyrin has been researched along with Prostatic Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Altug, V; Genze, F; Gschwend, JE; Hautmann, RE; Hofer, MD; Kuefer, R; Kunzi-Rapp, K; Zorn, C1
Altug, V; Bachem, M; Gschwend, JE; Hautmann, RE; Maier, S; Martin, R; Reich, E1

Other Studies

2 other study(ies) available for tributyrin and Prostatic Neoplasms

ArticleYear
Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer.
    British journal of cancer, 2004, Jan-26, Volume: 90, Issue:2

    Topics: Administration, Oral; Animals; Apoptosis; Blotting, Western; Butyrates; Disease Models, Animal; Gene Expression Regulation; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Retinoblastoma Protein; Transplantation, Heterologous; Triglycerides; Tumor Cells, Cultured

2004
Tributyrin induces differentiation, growth arrest and apoptosis in androgen-sensitive and androgen-resistant human prostate cancer cell lines.
    International journal of cancer, 2000, Oct-15, Volume: 88, Issue:2

    Topics: Androgens; Apoptosis; Butyrates; Cell Cycle; Cell Differentiation; Cell Division; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Male; Prostatic Neoplasms; Triglycerides; Tumor Cells, Cultured

2000